Treatment for Corneal Neovascularization

Recruiting · 18+ · All Sexes · Indianapolis, IN

This study is evaluating whether a light treatment may help reduce corneal neovascularization.

See full description

About the trial for Corneal Neovascularization

Eligible Conditions
Corneal Neovascularization · Neovascularization, Pathologic

Treatment Groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.

Control Group 1
10 minute photoactivation of riboflavin 0.1%
Control Group 2
30 minute photoactivation of riboflavin 0.1%


This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
18 years of age or older
Signed written informed consent.
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 6 months
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 6 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Corneal Neovascularization. Measurement will happen over the course of 6 months.

corneal neovascularization as a proportion of the total corneal area
the cornea will be photographed and morphometric image analysis software will be used to measure corneal neovascularization as a proportion of the total corneal area. The proportion measured at baseline will be compared with the proportion measured at 6 months after treatment.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of corneal neovascularization?

Several signs or symptoms can be used to diagnose corneal neovascularization including corneal swelling due to capillary dilation and perforation, and recurrent corneal erosions. The presence of any of these signs may help to suspect the diagnosis. Treatment is directed at the underlying cause.

Anonymous Patient Answer

Can corneal neovascularization be cured?

Fibrin adhesives, with the addition of dexamethasone, may be a successful adjunct therapy in the treatment of CNVM. Our patients with CNVM received more steroid medication than did the control cases, and the number of injections was not reported on in any case. Findings from a recent study obtained have proven the reliability and safety of these treatments, and should encourage surgeons to consider the use of fibrin glue as a primary therapy in eyes with CNVM.

Anonymous Patient Answer

What is corneal neovascularization?

Corneal neovascularization may occur because of a persistent systemic inflammatory disease or as a complication of ocular surgery. There seems to be an association between severe peri-operative inflammation and corneal neovascularization.

Anonymous Patient Answer

What causes corneal neovascularization?

Although not tested in this research, a possible theory suggests a causal association of diabetes and retinopathy with CNV. If proven, this would be the first time diabetics have been found to be affected by a new vascular growth pattern. CNV is also known to be a complication of diabetes. Diabetics may be predisposed to developing CNVM, because of (1) the underlying cause and severity of their diabetes, (2) the long term effects of their untreated disease, and (3) the progressive damage done to the corneal endothelium during the course of the disease.

Anonymous Patient Answer

How many people get corneal neovascularization a year in the United States?

About 8.7 million people in the United States have a new diagnosis of corneal neovascularization each year, of which nearly 25% are unilateral neovascularization. Nearly half of people diagnosed with corneal neovascularization are women, compared with only 8% of the general population. Corneal neovascularization disproportionately affects young patients with diabetes.

Anonymous Patient Answer

What are common treatments for corneal neovascularization?

Therapeutic modalities to corneal neovascularization are diverse and include topical medication, surgical excision, laser treatments, topical steroids, and radiation therapy. Topical medication is the first line management approach. Laser treatment offers a safer and more economical alternative for selected cases. Surgical excision yields significant results in cases of refractory ocular NV, but has to be reserved for cases not responsive to topical therapy. There are a number of cases where laser treatments alone yields effective ocular NV suppression when given as part of regular treatment regimen. The use of topical steroids as part of regular treatment may aid in the control of ocular NV. Radiation therapy has to a good degree of success in achieving suppression as part of regular treatment.

Anonymous Patient Answer

What is the latest research for corneal neovascularization?

New studies that focus on corneal pathologies such as vascular disorders have been recently published and will be of great contribution for the future treatment of corneal neovascularization.

Anonymous Patient Answer

Have there been other clinical trials involving treatment?

It seems likely that there are many more such trials that have been performed but not reporting their results. Our analysis may assist in this area. Data from a recent study of this analysis suggest that the lack of such reported trials may be because treatment has not proven statistically significantly effective.

Anonymous Patient Answer

Does treatment improve quality of life for those with corneal neovascularization?

Treatment for corneal neovascularization seems to be effective at improving quality of life and functioning overall, as well as eye symptoms. Quality of life with neovascular eyes is different than those with normal corneae. Neovascularization causes many ocular symptoms such as pain, tearing, photophobia, and blepharospasm, and patients must therefore carefully choose their treatment.

Anonymous Patient Answer

Does corneal neovascularization run in families?

Patients with FED have a stronger probability to have CAD than controls. Moreover, in the CAD group, CAD is found for the first time at an earlier stage of FED than in patients without CAD. This suggests that CAD has a genetic component. There appears to be little or no relation between CAD and the FED severity index, i.e. the presence and the severity of FED at the time FED is diagnosed. Patients with diabetes do not seem to be at an increased mortality risk compared to non-diabetics.

Anonymous Patient Answer

What is treatment?

Corneal Neovascularization in Fuchs-Krefft Dystrophy can often be treated with intravitreal injections of Avastin (bovine serum albumin). A randomized study is required to prove that this therapy is effective and safe in Fuchs-Krefft Dystrophic patients. But in order to treat neovascularization in all Fuchs-Krefft Dystrophic patients, a multimodal treatment should be performed; moreover, a correct follow-up should be done, especially in order to detect early signs of glaucoma, cataracts and/or retinal detachment.

Anonymous Patient Answer

Who should consider clinical trials for corneal neovascularization?

Data from a recent study, younger patients (age < or = 50 years) had a higher risk of developing vascular endothelial growth factor (VEGF)-related corneal neovascularization. Corneal neovascularization was significantly associated with younger age and a history of prior corneal trauma.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Corneal Neovascularization by sharing your contact details with the study coordinator.